Article
Infectious Diseases
Matthew Dryden, Michal Kantecki, Jean Li Yan, Gregory G. Stone, Heidi Leister-Tebbe, Mark Wilcox
Summary: This study aimed to evaluate the efficacy and safety of ceftaroline fosamil compared to comparators in patients with community-acquired pneumonia or complicated skin and soft-tissue infection and secondary bacteraemia. The results showed generally favorable outcomes for ceftaroline fosamil in terms of clinical and microbiological responses.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Microbiology
M. Edlinger-Stanger, V al Jalali, M. Andreas, W. Jaeger, M. Boehmdorfer, M. Zeitlinger, D. Hutschala
Summary: This study evaluated the pharmacokinetics of high-dose ceftaroline in plasma and lung tissue in cardiac surgery patients, showing that continuous administration achieved higher drug concentrations in lung tissue and a significantly longer time above the minimal inhibitory concentration compared to intermittent administration, supporting its use for pneumonia caused by susceptible pathogens in critically ill patients undergoing major cardiothoracic surgery.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Review
Respiratory System
Antoni Torres, Alona Kuraieva, Gregory G. Stone, Catia Cilloniz
Summary: Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a variety of problematic infections in the community and healthcare settings, including pneumonia, with severe disease and high mortality rates. Ceftaroline fosamil has been shown to be a possible alternative treatment for MRSA pneumonia.
EUROPEAN RESPIRATORY REVIEW
(2023)
Article
Infectious Diseases
Dmitri Guz, Maayan Bracha, Yotam Steinberg, Dror Kozlovsky, Anat Gafter-Gvili, Tomer Avni
Summary: This study compared the efficacy of ceftriaxone and ampicillin in the treatment of hospitalized adults with community-acquired pneumonia (CAP). The results showed no significant difference in 30-day all-cause mortality between the two treatment groups, but the ampicillin group had a significantly lower rate of Clostridioides difficile infection (CDI). Further research is needed to confirm these results.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Infectious Diseases
Catia Cilloniz, Raul Mendez, Hector Peroni, Carolina Garcia-Vidal, Veronica Rico, Albert Gabarrus, Rosario Menendez, Antoni Torres, Alex Soriano
Summary: The study found that empirically using ceftaroline in hospitalized patients with severe CAP is associated with a decreased risk of in-hospital mortality.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2022)
Review
Pediatrics
Susanna Esposito, Timothy J. Carrothers, Todd Riccobene, Gregory G. Stone, Michal Kantecki
Summary: Ceftaroline fosamil, a broad-spectrum beta-lactam antibiotic, has shown similar clinical and microbiological efficacy to existing treatments in pediatric patients with CAP/CABP or cSSTI/ABSSSI, with a safety profile consistent with cephalosporins. The drug may offer potential benefits in the management of these infections in children.
Article
Immunology
Stephen M. Bart, Daniel Rubin, Peter Kim, John J. Farley, Sumathi Nambiar
Summary: Recent analysis of Phase 3 noninferiority trials for hospital-acquired and ventilator-associated bacterial pneumonia revealed higher 28-day all-cause mortality rates among ventilated patients. Factors such as age, residence, diagnosis, and bacterial infection type were associated with mortality risk. A. baumannii infections were more common in Eastern European and Asia/Pacific participants with ventilator-associated pneumonia.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Pharmacology & Pharmacy
Yi-Ning Dong, Ya-Kun Wang, Qian Li, Bo-Hao Tang, John van den Anker, Guo-Xiang Hao, Yi Zheng, Li-Yuan Tian, Dian-Ping You, Yue-E Wu, Wei Zhao
Summary: This study found that the concentration of ceftriaxone in epithelial lining fluid is 12 times higher than in plasma in children.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Infectious Diseases
Mark Wilcox, Jean Li Yan, Pedro L. Gonzalez, Matthew Dryden, Gregory G. Stone, Michal Kantecki
Summary: This analysis evaluated the impact of underlying comorbidities on clinical outcomes in patients with complicated skin and soft tissue infections (cSSTIs) treated with ceftaroline fosamil compared to vancomycin plus aztreonam. Regardless of age and comorbidities such as diabetes, peripheral vascular disease, and cancer/malignancy, outcomes were similar between the treatment groups. Subgroup analyses showed consistent efficacy and safety results with those of the overall cSSTI population.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Infectious Diseases
Chao Zhuo, Yijiang Huang, Wenyuan Liu, Jin-Fu Xu, Wei Yun Zhu, Gregory G. Stone, Jean Li Yan, Naglaa Mohamed
Summary: The analysis of efficacy and safety of ceftaroline fosamil in Chinese patients with moderate-to-severe CAP is consistent with the overall study population. Ceftaroline fosamil was both non-inferior and superior to ceftriaxone for empiric treatment of Chinese patients with moderate-to-severe CAP.
INFECTION AND DRUG RESISTANCE
(2022)
Review
Infectious Diseases
Hideo Kato, Mao Hagihara, Nobuhiro Asai, Jun Hirai, Yuka Yamagishi, Takuya Iwamoto, Hiroshige Mikamo
Summary: This systematic review and meta-analysis aimed to evaluate the effectiveness of ceftriaxone and sulbactam-ampicillin in the initial treatment of community-acquired pneumonia (CAP). The pooled analysis of four studies showed no significant differences in the clinical cure rates and mortality rates between patients treated with ceftriaxone and those treated with sulbactam-ampicillin. This study supports the current guidelines for CAP treatment, but further research is needed.
Article
Pharmacology & Pharmacy
Phylinda L. S. Chan, Lynn McFadyen, Andrea Quaye, Heidi Leister-Tebbe, Victoria M. Hendrick, Jennifer Hammond, Susan Raber
Summary: A model-informed drug development approach was used to select high-dose ceftaroline fosamil regimens for pediatric patients with Staphylococcus aureus infections, showing good prediction accuracy and helping determine appropriate dosing regimens for children.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
(2021)
Article
Microbiology
Andrea Orsi, Alexander Domnich, Stefano Mosca, Matilde Ogliastro, Laura Sticchi, Rosa Prato, Francesca Fortunato, Domenico Martinelli, Fabio Tramuto, Claudio Costantino, Vincenzo Restivo, Vincenzo Baldo, Tatjana Baldovin, Elizabeth Begier, Christian Theilacker, Eva Agostina Montuori, Rohini Beavon, Bradford Gessner, Giancarlo Icardi
Summary: This study aimed to assess the serotype-specific epidemiology of pneumococci among hospitalized older adults in Italy. The prevalence of pneumococcal infection among hospitalized CAP cases was 13.1%, with serotypes 3, 8, 22F, and 11A being the most common. PCV20, which includes these serotypes, plays an important role in preventing pneumonia in older adults.
Review
Infectious Diseases
Nathaniel Eraikhuemen, Daniel Julien, Alandra Kelly, Taylor Lindsay, Dovena Lazaridis
Summary: Lefamulin demonstrates both bactericidal and bacteriostatic activity against various pathogens, including gram-positive, fastidious gram-negative, and atypical pathogens. It is reported to have comparable efficacy to moxifloxacin in patients with community-acquired bacterial pneumonia. Lefamulin may be a safe alternative for adult patients who cannot receive respiratory fluoroquinolones.
INFECTIOUS DISEASES AND THERAPY
(2021)
Article
Infectious Diseases
Eric Utt, Michal Kantecki, Guillermo Cabezas-Camarero, Susanna Esposito
Summary: This study reports the antimicrobial susceptibility of various bacteria to ceftaroline and other antimicrobial agents collected from respiratory tract specimens worldwide, classified by age groups. It is found that regardless of age, the majority of bacteria showed high susceptibility to ceftaroline.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)